• We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.
  • We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and prognostic assays that help to save lives and improve the quality of life of cancer patients.

Partnering

OncoMark PartneringOncoMark has invested in R&D and in-licensing of IP for diagnostic assay development. We believe that partnering should begin as early as possible in the development process.

Every winning partnership starts with a simple decision Click for more details »

 Products

IHC-Mark and Biomarker Interpretation Workflow 
OncoMark's lead product in development is OncoMasTR,
a novel prognostic assay for early breast cancer. 

This multi biomarker panel will determine the risk of recurrance for early breast cancer patients as either high or low risk.

The assay will aid the clinicians to determine the best option treatments for their patients
 
View current products »
 

Research Projects



 

 

Subscribe to RSS FeedCompany News

OncoMark's RATHER project is co-funding a clinical trial to study a new investigational drug for difficult-to-treat breast cancers
 The progress of a large pan-European clinical trial (POSEIDON) into a novel targeted study drug for difficult to treat breast cancers was announced today by the collaborative RATHER project. » read more
September 2015 - OncoMark are awarded €2.7 million by the European Commission to develop a diagnostic assay for breast cancer
 OncoMark are pleased to announce they have been awarded €2.7 million by the European Commission, for the commercial development of a new Diagnostic test for breast cancer patients. » read more
August 2015 - OncoMark are recruiting an experienced Product Development Manager
OncoMark are currently seeking to recruit an experienced Product Development Manager to lead the development of new Cancer Diagnostic tests, post-discovery, through the regulated stages of commercial product development. » read more
August 2015- Mr Desmond O'Leary joins OncoMark as Chief Executive
We are pleased to announce the appointment of Mr Desmond O Leary to the position of Chief Executive Officer of OncoMark. Mr O Leary is an experienced executive with over 20 years in the diagnostic industry. He will lead OncoMark through the next phase of development to commercialise prognostics tests in the Oncology arena and penetrate a global market. » read more
February 2015 - OncoMark's RATHER PROJECT featured on Horizon2020 website (EU Framework for Research and Innovation)
The RATHER project has been featured in a news article on the Horizon 2020 website. RATHER is a consortium project funded originally by the European Commission's 7th Framework Programme of Research and Development. » read more

Vacancies

February 2016 - Senior Biostatistician vacancy
OncoMark are seeking to recruit a full-time Senior Biostatistician to use statistics to help guide the design of a new multi-gene Cancer Diagnostic test, by determination of key parameters of the final diagnostic assay. » read more
August 2015 - Diagnostic Product Development Manager vacancy
OncoMark are currently seeking to recruit an experienced Diagnostic Product Development Manager to lead the development of new Cancer Diagnostic tests, post-discovery, through the regulated stages of commercial product development. » read more